EU approves Gilead's Trodelvy for first-line metastatic TNBC
Go back to EU approves Gilead's Trodelvy for first-line metastatic TNBC| Gilead Sciences (NASDAQ: GILD) | Delayed: 145.74 +2.02 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.72 | 52 Week High | $108.63 | |||
| Open | $144.26 | 52 Week Low | $71.39 | |||
| Day High | $146.22 | P/E | 80.52 | |||
| Day Low | $143.71 | EPS | $1.81 | |||
| Volume | 2,075,309 | |||||
